Aprea Therapeutics company info

What does Aprea Therapeutics do?
Aprea Therapeutics (NASDAQ:APRE) is a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Aprea is driven by a commitment to advance science and improve the lives of patients suffering from various types of cancer. Its flagship project, the p53 reactivator, represents a breakthrough approach in cancer treatment, targeting one of the most common mutations in cancer to restore the function of the p53 protein, often referred to as the "guardian of the genome" due to its role in controlling cell division and preventing tumor growth. The company's objectives include progressing its pipeline through clinical trials to commercialization, with a keen focus on safety, efficacy, and accessibility for cancer patients globally.
Aprea Therapeutics company media
Company Snapshot

Is Aprea Therapeutics a public or private company?


How many people does Aprea Therapeutics employ?


What sector is Aprea Therapeutics in?

pie chart
Health Care

Where is the head office for Aprea Therapeutics?

location pin
Head Office
Pennsylvania, United States

What year was Aprea Therapeutics founded?

founded flag
Year Founded
What does Aprea Therapeutics specialise in?
/Cancer Therapeutics /Drug Development /Clinical Trials /Epinova Program /APR-246 Drug /Healthcare Research

What are the products and/or services of Aprea Therapeutics?

Overview of Aprea Therapeutics offerings
A small molecule therapeutic aimed at reactivating mutant p53 tumor suppressor protein, focusing on hematologic and solid tumor cancers.
A proprietary technology platform for identifying and developing novel oncology therapies targeting the p53 pathway.
Clinical development services for advancing novel cancer therapies through various phases of clinical trials.
Collaborations with academic and pharmaceutical partners to discover and develop p53-based cancer therapies.
Providing access to a library of small molecules for potential therapeutic development in oncology.
Development of biomarker-driven diagnostics to identify patients most likely to benefit from their p53 targeted therapies.

Who is in the executive team of Aprea Therapeutics?

Aprea Therapeutics leadership team
  • Dr. Oren  Gilad Ph.D.
    Dr. Oren Gilad Ph.D.
    Co-Founder, CEO, President & Director
  • Mr. John P. Hamill CPA
    Mr. John P. Hamill CPA
    Senior VP, CFO, Principal Accounting Officer & Secretary
  • Dr. Dansu  Li Ph.D.
    Dr. Dansu Li Ph.D.
    Head of Technology
  • Dr. Lars B. Abrahmsen Ph.D.
    Dr. Lars B. Abrahmsen Ph.D.
    Senior VP & Chief Scientific Officer
  • Dr. Michel  Afargan Ph.D.
    Dr. Michel Afargan Ph.D.
    Head of Pharmacology Development
  • Mr. Ze'ev  Weiss B.Sc., C.P.A.
    Mr. Ze'ev Weiss B.Sc., C.P.A.
    Chief Business Advisor
  • Ms. Andrea  Epstein
    Ms. Andrea Epstein